Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
Aktis scores a plenary, as do Tyra’s FGFR3 inhibitor and Arcus’s HIF-2α contender.
The group will present the first clinical data on its KRAS G12D-selective project RMC-9805.
The group reports responses with its CD123-targeting ADC, but cash is running short.
Mevrometostat is the only EZH2 inhibitor in phase 3 for prostate cancer.
GDC-7035 enters the clinic, as does another bispecific against PD-L1 and VEGF.
The first approval for TAR-200 is on the horizon, setting up a challenge to Keytruda.